ImmunityBio shares surged as much as 14% on Wednesday, reaching their highest level in nearly seven weeks while lifting ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

Agenus (AGEN) announced publication in the Journal of Clinical Oncology showcasing data from its study of botensilimab in combination with ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Baseline geriatric vulnerabilities and QOL scores are associated with survival after chemotherapy in older adults with metastatic pancreatic cancer, researchers found.

For patients with resectable esophageal adenocarcinoma, perioperative chemotherapy with FLOT leads to improved survival.

OQY-3258, also known as ESG401, is an anti-TROP2 ADC currently under evaluation in three clinical trials: A Phase 1a/1b clinical trial for patients with solid tumors (NCT04892342). A Phase 3 study in ...

ITM Radiopharma has announced that its Phase III trial examining its gastroenteropancreatic tumour treatment, ITM-11, met its ...

First-line maintenance (1LM) niraparib significantly extends progression-free survival (rwPFS) and time to next treatment ...

Roche’s freshly approved PI3K inhibitor Itovebi can help extend the lives of certain patients with breast cancer when used in ...

Published results showed patients with chronic inflammatory diseases, such as rheumatoid arthritis and lupus, may have ...

In this article, Cerba dives into CAR+ T-cell therapy, from patient treatment to solutions for minimal residual disease (MRD) ...